

BioPhausia

PRESSRELEASE

BioPhausia – positive results BP04

Preclinical studies within project BP04 (more effective cancer treatment with cytostatics) shows proof of concept at four levels.

Earlier information

1. Treatment with BP04 decreases the pressure in the tumour (basic mechanism of action).
2. Increased uptake of marker in tumour has been documented

Studies recently reported show:

3. Treatment with BP04 induces increased uptake of cytostatics (in tumour tissue).
4. In a model designed to study the effects of tumour growth the results show a significant decrease of tumour growth (and a tendency to decrease tumour size) compared with a control-group.

Altogether, these studies give a good base to take the project to the clinical development phase. The project is according to plan and is in the next development phase.

Next step is to start a development company aimed at increased focus on the project as well as the financing of the project development.

This will probably be done in cooperation with an external partner according to the company development policy and business model.

Royalty income from Perfadex® to BioPhausia

BioPhausia is happy to acknowledge that Perfadex®, a previous BioPhausia project, which was divested in March 1999 as a registered product to Vitrolife AB in Gothenburg, has recently received FDA approval. The agreement with Vitrolife gives BioPhausia royalty income from the sales of Perfadex®.

BioPhausia AB (Medisan Pharmaceuticals AB) will be participating in the International congress in Brussels. "The 21st International Symposium on Intensive Care and Emergency care, Brussels Congress Center March 20-31 2001". Further information at exhibition stand at site and by phone.

Uppsala, Sweden March 19, 2001

For further information, please contact:

Soili Longsén, President BioPhausia AB + 46-18 34 99 00 or mobile +46-708 -32 92 19

Claes Thulin, Chairman of the Board +46-708 - 99 34 50

BioPhausia AB (publ)
AR 4, S-741 74 Uppsala, Sweden
Phone: +46 18 34 99 00
Fax: +46 18 34 94 95
E-mail: info@biophausia.se
Org.nr. 556485-0153

BioPhausia AB (publ)
AR 4, S-741 74 Uppsala, Sweden
Phone: +46 18 34 99 00
Fax: +46 18 34 94 95
E-mail: info@biophausia.se
Org.nr. 556485-0153